Role of β3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis

Hepatology

Volumn 50, Issue 6, 2009, Pages 1924-1935

  Trebicka, Jonel ^a   Hennenberg, Martin ^a   Pröbsting, Andrea Schulze ^a   Laleman, Wim ^b   Klein, Sabine ^a   Granzow, Michaela ^a   Nevens, Frederik ^b   Zaagsma, Johan ^c   Heller, Jörg ^a   Sauerbruch, Tilman ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; BETA 3 ADRENERGIC RECEPTOR; CYCLIC AMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; NITRIC OXIDE; RHO KINASE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; MESSENGER RNA; PROPANOLAMINE DERIVATIVE; PROPRANOLOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; LIVER BLOOD FLOW; LIVER CIRRHOSIS; LIVER PERFUSION; MESENTERIC ARTERY; NONHUMAN; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; STELLATE CELL; UPREGULATION; VASCULAR RESISTANCE; VASODILATATION; ANIMAL; GENETICS; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CYCLIC AMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; HEPATIC STELLATE CELLS; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; PROPANOLAMINES; PROPRANOLOL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, ADRENERGIC, BETA-3; RNA, MESSENGER; VASCULAR RESISTANCE;

EID: 73149117594     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23222     Document Type: Article

References (54)

1. Ekataksin W, Kaneda K. Liver microvascular architecture: an insight into the pathophysiology of portal hypertension. Semin Liver Dis 1999;19:359-382.
2. Hennenberg M, Trebicka J, Sauerbruch T, Heller J. Mechanisms of extrahepatic vasodilation in portal hypertension. Gut 2008;57:1300-1314.
3. Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. HEPATOLOGY 2007;46:242-253.
4. Trebicka J, Leifeld L, Hennenberg M, Biecker E, Eckhardt A, Fischer N, et al. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. HEPATOLOGY 2008;47:1264-1276.
5. Hennenberg M, Biecker E, Trebicka J, Jochem K, Zhou Q, Schmidt M, et al. Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology 2006;130:838-854.
6. Hennenberg M, Trebicka J, Biecker E, Schepke M, Sauerbruch T, Heller J. Vascular dysfunction in human and rat cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins. HEPATOLOGY 2007;45:495-506.
7. Zhou Q, Hennenberg M, Trebicka J, Jochem K, Leifeld L, Biecker E, et al. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut 2006;55:1296-1305.
8. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000;32:141-156.
9. Heller J, Trebicka J, Shiozawa T, Schepke M, Neef M, Hennenberg M, et al. Vascular, hemodynamic and renal effects of low-dose losartan in rats with secondary biliary cirrhosis. Liver Int 2005;25:657-666.
10. Lebrec D, Hillon P, Munoz C, Goldfarb G, Nouel O, Benhamou JP. The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study. HEPATOLOGY 1982;2:523-527.
11. Clement K, Vaisse C, Manning BS, Basdevant A, Guy-Grand B, Ruiz J, et al. Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med 1995;333:352-354.
12. Arch JR. The brown adipocyte beta-adrenoceptor. Proc Nutr Soc 1989;48:215-223.
13. Zaagsma J, Nahorski SR. Is the adipocyte beta-adrenoceptor a prototype for the recently cloned atypical beta 3-adrenoceptor? Trends Pharmacol Sci 1990;11:3-7.
14. Gauthier C, Tavernier G, Charpentier F, Langin D, Le Marec H. Functional beta3-adrenoceptor in the human heart. J Clin Invest 1996;98:556-562.
15. Moniotte S, Kobzik L, Feron O, Trochu JN, Gauthier C, Balligand JL. Upregulation of beta (3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation 2001;103:1649-1655.
16. Morimoto A, Hasegawa H, Cheng HJ, Little WC, Cheng CP. Endogenous beta3-adrenoreceptor activation contributes to left ventricular and cardiomyocyte dysfunction in heart failure. Am J Physiol Heart Circ Physiol 2004;286:H2425-2433.
17. Matsushita M, Horinouchi T, Tanaka Y, Tsuru H, Koike K. Characterization of beta 3-adrenoceptor-mediated relaxation in rat abdominal aorta smooth muscle. Eur J Pharmacol 2003;482:235-244.
18. Rautureau Y, Toumaniantz G, Serpillon S, Jourdon P, Trochu JN, Gauthier C. Beta 3-adrenoceptor in rat aorta: molecular and biochemical characterization and signalling pathway. Br J Pharmacol 2002;137:153-161.
19. Dessy C, Saliez J, Ghisdal P, Daneau G, Lobysheva II, Frerart F, et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation betablocker nebivolol. Circulation 2005;112:1198-1205.
20. Manara L, Badone D, Baroni M, Boccardi G, Cecchi R, Croci T, et al. Functional identification of rat atypical beta-adrenoceptors by the first beta 3-selective antagonists, aryloxypropanolaminotetralins. Br J Pharmacol 1996;117:435-442.
21. de Boer RE, Brouwer F, Zaagsma J. The beta-adrenoceptors mediating relaxation of rat oesophageal muscularis mucosae are predominantly of the beta 3-, but also of the beta 2-subtype. Br J Pharmacol 1993;110:442-446.
22. Lafontan M. Differential recruitment and differential regulation by physiological amines of fat cell beta-1, beta-2 and beta-3 adrenergic receptors expressed in native fat cells and in transfected cell lines. Cell Signal 1994;6:363-392.
23. Langin D, Tavernier G, Lafontan M. Regulation of beta 3-adrenoceptor expression in white fat cells. Fundam Clin Pharmacol 1995;9:97-106.
24. Chaudhry A, MacKenzie RG, Georgic LM, Granneman JG. Differential interaction of beta 1- and beta 3-adrenergic receptors with Gi in rat adipocytes. Cell Signal 1994;6:457-465.
25. Nantel F, Marullo S, Krief S, Strosberg AD, Bouvier M. Cell-specific down-regulation of the beta 3-adrenergic receptor. J Biol Chem 1994;269:13148-13155.
26. Shen YT, Zhang H, Vatner SF. Peripheral vascular effects of beta-3 adrenergic receptor stimulation in conscious dogs. J Pharmacol Exp Ther 1994;268:466-473.
27. Shen YT, Cervoni P, Claus T, Vatner SF. Differences in beta 3-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs. J Pharmacol Exp Ther 1996;278:1435-1443.
28. Gauthier C, Seze-Goismier C, Rozec B. Beta 3-adrenoceptors in the cardiovascular system. Clin Hemorheol Microcirc 2007;37:193-204.
29. Hollenga C, Brouwer F, Zaagsma J. Relationship between lipolysis and cyclic AMP generation mediated by atypical beta-adrenoceptors in rat adipocytes. Br J Pharmacol 1991;102:577-580.
30. Tamaoki J, Tagaya E, Isono K, Nagai A. Atypical adrenoceptor-mediated relaxation of canine pulmonary artery through a cAMP-dependent pathway. Biochem Biophys Res Commun 1998;248:722-727.
31. Kohout TA, Takaoka H, McDonald PH, Perry SJ, Mao L, Lefkowitz RJ, et al. Augmentation of cardiac contractility mediated by the human beta (3)-adrenergic receptor overexpressed in the hearts of transgenic mice. Circulation 2001;104:2485-2491.
32. Rozec B, Serpillon S, Toumaniantz G, Seze C, Rautureau Y, Baron O, et al. Characterization of beta3-adrenoceptors in human internal mammary artery and putative involvement in coronary artery bypass management. J Am Coll Cardiol 2005;46:351-359.
33. Cirino G, Sorrentino R, di Villa Bianca R, Popolo A, Palmieri A, Imbimbo C, et al. Involvement of beta 3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function. Proc Natl Acad Sci U S A 2003;100:5531-5536.
34. Sieber CC, Lopez-Talavera JC, Groszmann RJ. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology 1993;104:1750-1754.
35. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. Comparative pharmacology of human beta-adrenergic receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 2004;369:151-159.
36. Briones AM, Daly CJ, Jimenez-Altayo F, Martinez-Revelles S, Gonzalez JM, McGrath JC, Vila E. Direct demonstration of beta1- and evidence against beta2- and beta3-adrenoceptors, in smooth muscle cells of rat small mesenteric arteries. Br J Pharmacol 2005;146:679-691.
37. Leblais V, Pourageaud F, Ivorra MD, Marthan R, Muller B. Comparison of the alpha-adrenoceptor-mediated effects of beta3-adrenoceptor ligands in rat pulmonary artery. Naunyn Schmiedebergs Arch Pharmacol 2005;371:535-539.
38. Vrydag W, Michel MC. Tools to study beta3-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 2007;374:385-398.
39. Laleman W, Van Landeghem L, Van der Elst I, Zeegers M, Fevery J, Nevens F. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. Gastroenterology 2007;132:709-719.
40. Seglen PO. Preparation of isolated rat liver cells. Methods Cell Biol 1976;13:29-83.
41. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. HEPATOLOGY 2002;35:478-491.
42. Van de Casteele M, Sagesser H, Zimmermann H, Reichen J. Characterisation of portal hypertension models by microspheres in anaesthetised rats: a comparison of liver flow. Pharmacol Ther 2001;90:35-43.
43. Hakkinen JP, Miller MW, Smith AH, Knight DR. Measurement of organ blood flow with coloured microspheres in the rat. Cardiovasc Res 1995;29:74-79.
44. Hoiting BH, Meurs H, Schuiling M, Kuipers R, Elzinga CR, Zaagsma J. Modulation of agonist-induced phosphoinositide metabolism, Ca2+ signalling and contraction of airway smooth muscle by cyclic AMP-dependent mechanisms. Br J Pharmacol 1996;117:419-426.
45. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-218.
46. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134:1655-1669.
47. Laleman W, Van Landeghem L, Severi T, Vander Elst I, Zeegers M, Bisschops R, et al. Both Ca2+-dependent and -independent pathways are involved in rat hepatic stellate cell contraction and intrahepatic hyperresponsiveness to methoxamine. Am J Physiol Gastrointest Liver Physiol 2007;292:G556-564.
48. Gauthier C, Tavernier G, Trochu JN, Leblais V, Laurent K, Langin D, et al. Interspecies differences in the cardiac negative inotropic effects of beta (3)-adrenoceptor agonists. J Pharmacol Exp Ther 1999;290:687-693.
49. Brahmadevara N, Shaw AM, MacDonald A. Alpha1-adrenoceptor antagonist properties of CGP 12177A and other beta-adrenoceptor ligands: evidence against beta (3)- or atypical beta-adrenoceptors in rat aorta. Br J Pharmacol 2004;142:781-787.
50. Bristow MR, Minobe WA, Raynolds MV, Port JD, Rasmussen R, Ray PE, et al. Reduced beta 1 receptor messenger RNA abundance in the failing human heart. J Clin Invest 1993;92:2737-2745.
51. Oben JA, Roskams T, Yang S, Lin H, Sinelli N, Torbenson M, et al. Hepatic fibrogenesis requires sympathetic neurotransmitters. Gut 2004;53:438-445.
52. Sancho-Bru P, Bataller R, Colmenero J, Gasull X, Moreno M, Arroyo V, et al. Norepinephrine induces calcium spikes and proinflammatory actions in human hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2006;291:G877-G884.
53. Seyde WC, Longnecker DE. Anesthetic influences on regional hemodynamics in normal and hemorrhaged rats. Anesthesiology 1984;61:686-698.
54. Geraghty JG, Angerson WJ, Carter DC. Portal venous pressure and portasystemic shunting in experimental portal hypertension. Am J Physiol 1989;257:G52-G57.